Alimentary Pharmacology & Therapeutics

The management of severe ulcerative colitis
pp. 419-424(6)
Authors: Hyde, G. M.; Jewell, D. P.

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome
pp. 425-443(19)
Authors: Wilcox, C. M.; Mönkemüller, K. E.

Liver transplantation
pp. 445-451(7)
Author: O'Grady, J. G.

Nutritional support
pp. 453-471(19)
Authors: Ofman, J.; Koretz, R. L.

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials
pp. 473-482(10)
Authors: Carlsson, R.; Galmiche, J.-P.; Dent, J.; Lundell, L.; Frison, L.

The effect of decaffeination of coffee on gastro-oesophageal reflux in patients with reflux disease
pp. 483-486(4)
Authors: Pehl, C.; Pfeiffer, A.; Wendl, B.; Kaess, H.

Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial
pp. 487-495(9)
Authors: McDougall, N. I.; Watson, R. G. P.; Collins, J. S. A.; McFarland, R. J.; Love, A. H. G.

Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis
pp. 497-503(7)
Authors: Schütze, K.; Bigard, M. A.; Waes, L. van; Hinojosa, J.; Bedogni, G.; Hentschel, E.

The long-term management of patients with bleeding duodenal ulcers
pp. 505-510(6)
Authors: McAlindon, M. E.; Taylor, J. S. W.; Ryder, S. D.

Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection
pp. 511-514(4)
Authors: Kihira, K.; Satoh, K.; Saifuku, K.; Taniguchi, Y.; Takimoto, T.; Yamamoto, H.; Ido, K.; Yoshida, Y.; Kimura, K.

Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients
pp. 515-522(8)
Authors: Labenz, J.; Beker, J.A.; Dekkers, C.P.M.; Farley, A.; Klör, H.-U.; Jönsson, A.

Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori
pp. 523-527(5)
Authors: Breuer, T.; Kim, J. G.; Gurer, I. E.; Graham, D. P.; Osato, M.; Genta, R. M.; Graham, D. Y.

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection
pp. 529-532(4)
Authors: Segura, A. M.; Gutiérrez, O.; Otero, W.; Angel, A.; Genta, R. M.; Graham, D. Y.

Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week
pp. 533-535(3)
Authors: Zwet, A. A. van; Thijs, J. C.; Wouden, E. J. van der; Kooy, A.

Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin
pp. 537-540(4)
Authors: Lim, A. G.; Walker, C.; Chambers, S.; Gould, S. R.

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice
pp. 541-546(6)
Authors: Jones, R. H.; Baxter, G.

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome
pp. 547-552(6)
Authors: Hahn, B. A.; Kirchdoerfer, L. J.; Fullerton, S.; Mayer, E.

Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life
pp. 553-559(7)
Authors: Hahn, B. A.; Kirchdoerfer, L. J.; Fullerton, S.; Mayer, E.

Zamifenacin (UK-76, 654), a potent gut M₃ selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome
pp. 561-568(8)
Authors: Houghton, L. A.; Rogers, J.; Whorwell, P. J.; Campbell, F. C.; Williams, N. S.; Goka, J.

The absorption of low-dose methotrexate in patients with inflammatory bowel disease
pp. 569-573(5)
Authors: Moshkowitz, M.; Oren, R.; Tishler, M.; Konikoff, F. M.; Graff, E.; Brill, S.; Yaron, M.; Gilat, T.

Effect of acute pentoxifylline treatment in an experimental model of colitis
pp. 575-580(6)
Authors: Peterson, T. C.; Davey, K.

Studies of water and electrolyte movement from oral rehydration solutions (rice- and glucose-based) across a normal and secreting gut using a dual isotope tracer technique in a rat perfusion model
pp. 581-587(7)
Authors: Wall, C. R.; Bates, M. S.; Cleghorn, G. J.; Ward, L.

Transdermal delivery of erythromycin lactobionate—implications for the therapy of gastroparesis
pp. 589-592(4)
Authors: Brand, R. M.; Lof, J.; Quigley, E. M. M.

Gastric emptying of semisolid meal unaltered by 3 days' administration of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate
pp. 593-597(5)
Authors: Stacher, G.; Bergmann, H.; Stacher-Janotta, G.; Schneider, C.; Steinringer, H.

Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus
pp. 599-603(5)
Authors: Annese, V.; Lombardi, G.; Frusciante, V.; Germani, U.; Andriulli, A.; Bassotti, G.

Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration
pp. 605-612(8)
Authors: Tanaka, S.; Guth, P. H.; Carryl, O. R.; Kaunitz, J. D.

Suppressive effect of tetraprenylacetone on gastric atrophy induced by short-term administration of N-methyl-N^′-nitro- N-nitrosoguanidine in rats
pp. 613-618(6)
Authors: Miwa, H.; Nagahara, A.; Wada, R.; Hirai, S.; Endo, K.; Watanabe, S.; Sato, N.

NSAIDs upregulate β₂-integrin expression on human neutrophils through a calcium-dependent pathway
pp. 619-630(12)
Authors: Fiorucci, S.; Santucci, L.; Gerli, R.; Brunori, P. M.; Federici, B.; Ugolini, B.; Fabbri, C.; Morelli, A.